Clinical Trial Update: Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML [EARLY_Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and preliminary efficacy of CLL1 and CD38 dual CAR-T cells in relapsed/refractory acute myeloid leukemia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CLL1 and CD38 Dual CAR-T

Snippet

Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Conditions: Acute Myeloid Leukemia | EARLY_Phase 1 | Status: TERMINATED